Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eva Meluzinova

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Journal of the American Academy of Dermatology|February 18, 2014
Management of psoriasis vulgaris and multiple sclerosis with fumaric acidSpyridon Gkalpakiotis, Petr Arenberger, Petra Gkalpakioti, et al.
Translational Neuroscience|October 28, 2022
Prevalence of neurodegenerative/demyelinating disorders in patients with achalasiaMartin Jerie, Zuzana Vackova, Zdenek Vojtech, et al.
Plos One|July 7, 2018
Health-related quality of life, neuropsychiatric symptoms and structural brain changes in clinically isolated syndromeEva Hyncicova, Adam Kalina, Martin Vyhnalek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2020
Elevated D-dimer as an immediate response to alemtuzumab treatmentJana Libertinova, Eva Meluzinova, Eva Nema, et al.
Brain and Behavior|March 16, 2017
MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patientsJana Libertinova, Eva Meluzinova, Vaclav Matoska, et al.
Multiple Sclerosis and Related Disorders|March 3, 2022
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech RepublicPavel Hradilek, Eva Meluzinova, Olga Zapletalova, et al.
Plos One|January 13, 2017
Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβJana Libertinova, Eva Meluzinova, Ales Tomek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2011
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Therapeutics and Clinical Risk Management|October 31, 2017
Understanding the positive benefit:risk profile of alemtuzumab in relapsing multiple sclerosis: perspectives from the Alemtuzumab Clinical Development ProgramEva Havrdova, Jeffrey A Cohen, Dana Horakova, et al.
Journal of the American Academy of Dermatology|February 18, 2014
Management of psoriasis vulgaris and multiple sclerosis with fumaric acidSpyridon Gkalpakiotis, Petr Arenberger, Petra Gkalpakioti, et al.
Translational Neuroscience|October 28, 2022
Prevalence of neurodegenerative/demyelinating disorders in patients with achalasiaMartin Jerie, Zuzana Vackova, Zdenek Vojtech, et al.
Plos One|July 7, 2018
Health-related quality of life, neuropsychiatric symptoms and structural brain changes in clinically isolated syndromeEva Hyncicova, Adam Kalina, Martin Vyhnalek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|February 21, 2020
Elevated D-dimer as an immediate response to alemtuzumab treatmentJana Libertinova, Eva Meluzinova, Eva Nema, et al.
Brain and Behavior|March 16, 2017
MxA mRNA decrease preceding NAb detection in IFNβ-treated MS patientsJana Libertinova, Eva Meluzinova, Vaclav Matoska, et al.
Multiple Sclerosis and Related Disorders|March 3, 2022
Is pregnancy in MS patients safe and what is its impact on MS course? Real World evidence of 1533 pregnancies in Czech RepublicPavel Hradilek, Eva Meluzinova, Olga Zapletalova, et al.
Plos One|January 13, 2017
Myxovirus Resistance Protein A mRNA Expression Kinetics in Multiple Sclerosis Patients Treated with IFNβJana Libertinova, Eva Meluzinova, Ales Tomek, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 1, 2011
Effect of BG-12 on contrast-enhanced lesions in patients with relapsing--remitting multiple sclerosis: subgroup analyses from the phase 2b studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Lancet (London, England)|October 31, 2008
Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb studyLudwig Kappos, Ralf Gold, David H Miller, et al.
Pageof 1